Ambrx Biopharma Inc. (AMAM)
NYSE: AMAM
· Real-Time Price · USD
28.00
0.02 (0.07%)
At close: Mar 06, 2024, 10:00 PM
Ambrx Biopharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 3.44M | 5.64M | 5.81M | 7.4M | 6.32M | 5.24M | 6.5M | 7.46M | 9.89M | 12.32M | 13M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 3.44M | 5.64M | 5.81M | 7.4M | 6.32M | 5.24M | 6.5M | 7.46M | 9.89M | 12.32M | 13M |
Operating Income | -69.5M | -52.54M | -62.15M | -63.78M | -72.99M | -83.36M | -67.23M | -62.23M | -47.88M | -32.37M | -22.74M |
Interest Income | 5.8M | 3.49M | 1.85M | 1.11M | 555.5K | n/a | n/a | n/a | 3K | 6K | 22.5K |
Pretax Income | -68.73M | -59.04M | -70.23M | -76.06M | -82.45M | -88.84M | -72.79M | -64.38M | -50.75M | -37.12M | -27.48M |
Net Income | -69.37M | -59.63M | -70.65M | -78M | -85.94M | -92.22M | -77.88M | -69.74M | -54.1M | -40.12M | -28.33M |
Selling & General & Admin | 28.9M | 25.77M | 24.69M | 22.72M | 21.1M | 19.47M | 19.14M | 18.27M | 15.54M | 12.8M | 10.2M |
Research & Development | 50.68M | 44.68M | 48.35M | 53.31M | 59.14M | 64.98M | 57.96M | 54.3M | 43.44M | 32.58M | 26.5M |
Other Expenses | 41.99M | 41.8M | 41.65M | 41.88M | -1.05M | -928K | -784K | n/a | n/a | n/a | n/a |
Operating Expenses | 46.08M | 4.46M | 7.05M | 10.27M | 5.52M | 767K | -37.34M | -71.84M | -60.64M | -49.43M | -40.48M |
Interest Expense | 4.88M | 9.35M | 13.68M | 13.49M | 10.67M | 6.2M | 1.66M | 1.66M | n/a | n/a | n/a |
Selling & Marketing Expenses | 1.94M | 2.62M | 2.62M | 2.32M | 1.99M | 1.65M | 2.02M | 1.44M | 1.12M | 814K | 1.15M |
Cost & Expenses | 14.03M | -27.59M | -25M | -30.72M | -35.47M | -40.23M | -78.33M | -71.84M | -60.64M | -49.43M | -40.48M |
Income Tax Expense | 636.5K | 599K | 423K | 1.94M | 3.49M | 3.38M | 3.25M | 1.66M | 622K | 1.24M | 1.24M |
Shares Outstanding (Basic) | 62.25M | 55.9M | 45M | 38.62M | 38.62M | 38.6M | 38.59M | 20.45M | 38.37M | 2.54M | 2.54M |
Shares Outstanding (Diluted) | 62.25M | 55.9M | 45M | 38.62M | 38.62M | 38.6M | 38.59M | 20.45M | 38.37M | 2.54M | 2.54M |
EPS (Basic) | -1.37 | -1.34 | -1.77 | -2.02 | -2.72 | -2.89 | -7.86 | -12.99 | -12.36 | -12.26 | -6.68 |
EPS (Diluted) | -1.37 | -1.34 | -1.77 | -2.02 | -2.72 | -2.89 | -7.86 | -12.99 | -12.36 | -12.26 | -6.68 |
EBITDA | -70.09M | -53.78M | -57.18M | -58.32M | -67.99M | -77.66M | -66.19M | -61.24M | -45.83M | -30.42M | -20.8M |
EBIT | -69.28M | -52.32M | -51.99M | -58.01M | -64.58M | -55.91M | -38.94M | -17.88M | -5.9M | -11.81M | -11.81M |
Depreciation & Amortization | 691K | 186K | 4.97M | 5.46M | 5M | 4.54M | -1.11M | -2.15M | -2.05M | -1.95M | -1.95M |